Please login to the form below

Not currently logged in
Email:
Password:

rocapuldencel-T

This page shows the latest rocapuldencel-T news and features for those working in and with pharma, biotech and healthcare.

Argos hit as kidney cancer immunotherapy fails phase III trial

Argos hit as kidney cancer immunotherapy fails phase III trial

Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime soon have been dashed after it flunked a pivotal phase III trial. ... Rocapuldencel-T, a personalised immunotherapy that uses individual patients' tumour

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics